Investigational drug · Phase 2
vilamakitug
Also called: XB2001, Natrunix
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA.
Phase 2Last checked: Nov 19, 2026Latest source record: May 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "vilamakitug"
First trial start
2026
Jul 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "vilamakitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Axial Spondyloarthritis
- Ankylosing Spondylitis
- r-axSpA
- Nr-axSpA
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Ankylosing spondylitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "vilamakitug" as an intervention, largest first.
- Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for EfficacyPivotal-lookingNot yet recruiting
XBiotech, Inc.Industry
NCT06526377 · 150 participants (planned) · Start Sep 2026 · Primary completion Sep 2028
Drug: vilamakitug; placebo · For: Axial Spondyloarthritis; Ankylosing Spondylitis; r-axSpA and 1 more
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of trifluridine/tipiracilߙ+/-ߙbevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.
Thibaudin M, Roussot N, Burlot C, et al. · Signal Transduct Target Ther 2025
- Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer.
Fumet JD, Roussot N, Bertaut A, et al. · Future Oncol 2024
- IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19.
Renieris G, Karakike E, Gkavogianni T, et al. · J Innate Immun 2022
Also in development for Axial Spondyloarthritis
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- SPY002-072SPY072Phase 22 trials
Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.